Skip to Main Content

Centessa, a biotech company that raised more than $300 million in an IPO earlier this year, has an early-stage treatment for hemophilia that might compete with the gene therapies nearing the market.

The company’s drug, a monthly treatment injected under the skin, significantly reduced the rate of bleeding for patients with hemophilia A and B in a small study, Centessa said Thursday. In the trial, which enrolled just 23 people and was not placebo-controlled, the highest dose of Centessa’s drug led to an 88% reduction in annualized bleeding rate compared to baseline after six months.


If that number holds up in larger, longer studies — which Centessa plans to conduct — the treatment’s efficacy might be comparable to that of gene therapies now in late-stage development. (Roche’s Hemlibra, a weekly treatment for hemophilia A, reduced bleeds by about 96%.)

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.